Zirconium Zr 89-girentuximab

Zirconium Zr 89-girentuximab - A radioimmunoconjugate comprised of the recombinant chimeric monoclonal antibody girentuximab, that binds an extracellular epitope of carbonic anhydrase IX CAIX, and labeled with the radioisotope zirconium 89 Zr 89 with potential use as an imaging agent upon positron emission tomography PET. The antibody moiety of zirconium Zr 89-girentuximab binds to CAIX expressed on tumor cells. Upon binding, the radioisotope moiety may be detected using PET, which enables the imaging and quantification of CAIX-expressing tumor cells. CAIX, a hypoxia-inducible transmembrane glycoprotein, is overexpressed on renal cell carcinoma RCC and various other tumors; it plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion.